La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Pharming a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Pharming..

Pharming (NASDAQ:PHAR) Azioni, Catena delle Opzioni

PHARMING GROUP NV - ADR

Pharming

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming Group

PHARMARON BEIJING U/ADR by PHARMARON BEIJING CO LTD.

PHARNEXT by Pharnext

PHarol SGPS SA

PharmChem Inc

PHARMA FOODS INTL CO by Pharma Foods International Co., Ltd.

Pharma Foods International Co Ltd

Pharma Mar SA

PHARM-BIO SERV INC by Pharma-Bio Serv, Inc.

Pharma-Bio Serv Inc

PharmaCielo Ltd

PHARMACOM BIOVET INC by PharmaCom BioVet, Inc.

PharmaCom BioVet Inc

PharmaCyte Biotech Inc

PHARMAROTH LABS INC by PharmaRoth Labs, Inc.

PharmaRoth Labs Inc

PHARMATHER HLDGS LTD by PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd

Pharmadrug Inc

Pharmagen Inc

PHARMAGREEN BIOTECH INC by Pharmagreen Biotech Inc.

Pharmagreen Biotech Inc

Pharmala Biotech Holdings Inc

PHARMALA BIOTECH HLDG INC by PharmAla Biotech Holdings Inc.

PHARMARON BEIJING CO LTD by PHARMARON BEIJING CO LTD.

Pharmaron Beijing Co Ltd

PHARMING GROUP NV ORD by Pharming Group NV

Pharnext SA

Pharos Energy PLC

Pharvaris NV

News

Management

Press Releases

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming Group to participate in February investor conference

Pharming Group to report fourth quarter and full year 2024 financial results on March 13

Pharming Group to participate in March investor conference

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Earnings

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

General

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

Pharming Group reports first quarter 2025 financial results and provides business update

PHAR

Akebia Therapeutics

Ardelyx

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Geron

Gyre Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

MiMedx Group

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Replimune Group

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Spyre Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Comments

Pharming

Pharming (PHAR) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO